

Prodotti scientifici (2021-2022)

- 1) Computational and Structural Analysis to Assess the Pathogenicity of Bardet-Biedl Syndrome Related Missense Variants Identified in Bardet-Biedl Syndrome 10 Gene (BBS10). Gupta N, Khan MA, Capasso G, Zacchia M. ACS Omega. 2022 Oct 12;7(42):37654-37662. doi: 10.1021/acsomega.2c04522
- 2) Metabolomic fingerprinting of renal disease progression in Bardet-Biedl syndrome reveals mitochondrial dysfunction in kidney tubular cells. Marchese E, Caterino M, Viggiano D, Cevenini A, Tolone S, Docimo L, Di Iorio V, Del Vecchio Blanco F, Fedele R, Simonelli F, Perna A, Nigro V, Capasso G, Ruoppolo M, Zacchia M. iScience. 2022 Sep 27;25(11):105230. doi: 10.1016/j.isci.2022.105230
- 3) Multi-Omics Studies Unveil Extraciliary Functions of BBS10 and Show Metabolic Aberrations Underlying Renal Disease in Bardet-Biedl Syndrome. Marchese E, Caterino M, Fedele R, Pirozzi F, Cevenini A, Gupta N, Ingrosso D, Perna A, Capasso G, Ruoppolo M, Zacchia M. Int J Mol Sci. 2022 Aug 20;23(16):9420. doi: 10.3390/ijms23169420.
- 4) miRNA-23a modulates sodium-hydrogen exchanger 1 expression: studies in medullary thick ascending limb of salt induced hypertensive rats. Lombardi P, Mallardo M, Petrazzuolo O, Nagoth JA, Fiume G, Scanni R, Iervolino A, Damiano S, Coppola A, Borriello M, Ingrosso D, Perna AF, Zacchia M, Trepiccione F, Capasso G. Nephrol Dial Transplant. 2022 Aug 3;37(8):2322-2332. doi: 10.1093/ndt/gfac232
- 5) Bardet-Biedl syndrome: The pleiotropic role of the chaperonin-like BBS6, 10, and 12 proteins. Gupta N, D'acerno M, Zona E, Capasso G, Zacchia M. Am J Med Genet. 2022 Aug 15;154(8):1785-1795. doi: 10.1002/ajmg.b.32600
- 6) Guidelines for Genetic Testing and Management of Alport Syndrome. Savige J, et al. Clinical JASN. 2022 Aug 15;17(8):1155-1165. doi: 10.2202/cjkn.2022.0015
- 7) Diffusion tensor imaging for the study of early renal dysfunction in patients affected by bardet-biedl syndrome. Borrelli P, Zacchia M, Cavaliere C, Basso L, Salvatore M, Capasso G, Aiello M. Sci Rep. 2021 Oct 21;11(1):20855. doi: 10.1038/s41598-021-01048-4
- 8) Nephroplex: a kidney-focused NGS panel highlights the challenges of PKD1 sequencing and identifies a founder BBS4 mutation. Zacchia M, Blanco FDV, Trepiccione F, Blasio G, Torella A, Melluso A, Capolongo G, Pollastro RM, Piluso G, Di Iorio V, Simonelli F, Viggiano D, Perna A, Nigro V, Capasso G. J Nephrol. 2021 May 8. doi: 10.1007/s40620-021-01048-4.
- 9) Consensus statement on standards and guidelines for the molecular diagnostics of Alport syndrome: refining the ACMG criteria. Savige J, Storey H, Watson E, Hertz JM, Deltas C, Renieri A, Mari F, Hilbert P, Plevova P, Byers P, Cerkauskaite A, Gregory M, Cerkauskiene R, Ljubanovic DG, Becherucci F, Errichiello C, Massella L, Aiello V, Lennon R, Hopkinson L, Koziell A, Lungu A, Rothe HM, Hoefele J, Zacchia M et al. Eur J Hum Genet. 2021 Aug;29(8):1186-1197. doi: 10.1038/s41431-021-00877-z
- 10) Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. Chertow GM et al, PRO2TECT Study Group. N Engl J Med. 2021 Apr 29;384(17):1589-1600. doi: 10.1056/NEJMoa2025000
- 11) Urinary proteomics reveals key markers of salt sensitivity in hypertensive patients during saline infusion. Matafora V, Lanzani C, Zagato L, Manunta P, Zacchia M, Trepiccione F, Simonini M, Capasso G, Bachi A. J Nephrol. 2021 Jun;34(3):739-751. doi: 10.1007/s40620-020-00877-z. Epub 2021 Jan 4.
- 12) Diagnostic issues faced by a rare disease healthcare network during Covid-19 outbreak: data from the Campania Rare Disease Registry. Limongelli G, Iucolano S, Monda E, Elefante P, De Stasio C, Lubrano I, Caiazza M, Mazzella M, Fimiani F, Galdo M, De Marchi G, Esposito M, Rubino M, Cirillo A, Fusco A, Esposito A, Trama U, Esposito S, Scarano G, Sepe J, Andria G, Orlando V, Menditto E, Chiodini P; Campania Rare Disease Network. J Public Health (Oxf). 2022 Aug 25;44(3):586-594. doi: 10.1093/pubmed/fdab137.

13) Cystinuria: an update on pathophysiology, genetics, and clinical management. D'Ambrosio V, Capolongo G, Goldfarb D, Gambaro G, Ferraro PM. *Pediatr Nephrol.* 2022 Aug;37(8):1705-1711. doi: 10.1007/s00467-021-05342-y. Epub 2021 Nov 23.

14) Cystinuria: clinical practice recommendation. Servais A, Thomas K, Dello Strologo L, Sayer JA, Bekri S, Bertholet-Thomas A, Bultitude M, Capolongo G, Cerkauskiene R, Daudon M, Doizi S, Gillion V, Gràcia-Garcia S, Halbritter J, Heidet L, van den Heijkant M, Lemoine S, Knebelmann B, Emma F, Levtchenko E; Metabolic Nephropathy Workgroup of the European Reference Network for Rare Kidney Diseases (ERKNet) and eUROGEN. *Kidney Int.* 2021 Jan;99(1):48-58. doi: 10.1016/j.kint.2020.06.035. Epub 2020 Sep 9.

15) Urinary epidermal growth factor/monocyte chemotactic peptide 1 ratio as non-invasive predictor of Mayo clinic imaging classes in autosomal dominant polycystic kidney disease. Rocchetti MT, Pesce F, Matino S, Piscopo G, di Bari I, Trepiccione F, Capolongo G, Perniola MA, Song X, Khowaja S, Haghghi A, Peters D, Paolicelli S, Pontrelli P, Netti GS, Ranieri E, Capasso G, Moschetta M, Pei Y, Gesualdo L; (Studio PRE. MED. (MEDicina di PREcisione) Prog.n.F/050065/01- 02/X32). *J Nephrol.* 2022 Nov 7. doi: 10.1007/s40620-022-01468-w. Online ahead of print